Chemed Corporation (CHE) - NYSE
  • May 10, 2013, 2:00 PM
    Chemed (CHE -5.3%) takes a hit from a negative Citron Research report calling it 'Game Over' for the shares. Citron says that the recent False Claims suit filed against the company's VITAS business units is just the tip of the spear. Not only has the analyst community overlooked a second, equally damaging suit that was filed, but the government's takeover of the investigation means a potential trebling of damages against the company.
    | May 10, 2013, 2:00 PM
  • May 3, 2013, 9:27 AM

    Chemed (CHE) -16.2% premarket after the U.S. sues the hospice chain and several of its subsidiaries, alleging they submitted false Medicare billings for services that misspent "tens of millions of taxpayer dollars." In one instance cited by the government, CHE subsidiary Vitas Hospice billed a patient for care he didn't need and at a time when he was actually playing bingo.

    | May 3, 2013, 9:27 AM
  • May 3, 2013, 9:10 AM
    Premarket gainers: PKT +32%. YRCW +27%. INVN +18%. YY +8%. DDD +5%.
    Losers: VCRA -35%. ZAGG -24%. GUID -23%. CHE -16%. ARNA -13%. CETV -13%. HMY -9%. LNKD -9%. AGNC -6%. RBS -6%.
    | May 3, 2013, 9:10 AM | 3 Comments
  • Nov. 2, 2012, 10:38 AM

    Chemed (CHE -3%) discloses in a regulatory filing that in July it received an investigative subpoena from the Florida Attorney General seeking a variety of documents - of which it had previously produced in the course of prior government investigations - regarding billing records and procedures, patient eligibility for hospice care, plus other matters pertaining to its general business operations.

    | Nov. 2, 2012, 10:38 AM | 1 Comment
  • Apr. 20, 2012, 12:55 PM

    Chemed (CHE -4.9%) dips after posting a mixed Q1, beating on revenue but coming up short on its EPS. Net earnings actually rose 13% on better growth in its hospice-care segment, but margins were pressured by sales declines in its Roto-Rooter business. The company also lowered the top end of its EPS estimate by a nickel, now expecting to earn between $5.35 - $5.50 per share.

    | Apr. 20, 2012, 12:55 PM
  • Feb. 15, 2012, 10:58 AM

    Chemed (CHE +3.9%) moves higher despite missing estimates on its Q4 report yesterday. Net income rose 14% Y/Y, weathering a drop in operating income from its Vitas hospice unit as its Roto-Rooter plumbing business offset the decline with a 28% jump in profit. The company also raises FY12 guidance, now expecting to earn $5.35 - $5.55 per share, above Street expectations of $5.27.

    | Feb. 15, 2012, 10:58 AM | 1 Comment
  • Jan. 5, 2012, 12:31 PM
    A Bloomberg report about the Justice Department joining a lawsuit against another hospice operator may be contributing to weakness in Chemed (CHE -1.9%) shares. DOJ and the Department of Health and Human Services are already investigating Chemed’s Vitas Healthcare, for “an extensive scheme” to defraud the government of “hundreds of millions of dollars."
    | Jan. 5, 2012, 12:31 PM
  • Nov. 16, 2011, 9:51 AM
    Shares of Chemed (CHE -7.9%) trade lower after a whistleblower accuses the firm of an extensive Medicare HMO scheme aimed at defrauding the government. The allegations were unveiled in a lawsuit filed in a federal case against the company.
    | Nov. 16, 2011, 9:51 AM
  • Nov. 7, 2011, 2:28 PM

    Chemed (CHE +2.4%) ticks higher after its board approves an additional $100M to the current buyback program it initiated in February, as the operator of Vitas Healthcare and Roto-Rooter looks to boost the value of its stock.

    | Nov. 7, 2011, 2:28 PM
Company Description
Chemed Corp. operates as a holding company. The company operates business through two segments: The VITAS Healthcare and Roto-Rooter Group. The VITAS Healthcare segment provides hospice services to patients through a network of physicians, registered nurses, home health aides, social workers,... More
Sector: Healthcare
Industry: Home Health Care
Country: Russia